Total Payments
$4,467
2021 Payments
$1,182
Companies
15
Transactions
124
Medicare Patients
714
Medicare Billing
$109,324
Payment Breakdown by Category
Food & Beverage$3,350 (75.0%)
Consulting$750.00 (16.8%)
Education$367.49 (8.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,350 | 112 | 75.0% |
| Consulting Fee | $750.00 | 1 | 16.8% |
| Education | $367.49 | 11 | 8.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $953.01 | 22 | $0 (2021) |
| Theratechnologies Inc. | $937.64 | 10 | $0 (2021) |
| Astellas Pharma US Inc | $683.20 | 14 | $0 (2019) |
| Janssen Products, LP | $635.24 | 10 | $0 (2021) |
| ViiV Healthcare Company | $553.31 | 33 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $232.88 | 15 | $0 (2021) |
| Janssen Biotech, Inc. | $150.28 | 7 | $0 (2021) |
| Allergan Inc. | $147.59 | 4 | $0 (2019) |
| Seqirus USA Inc | $35.45 | 2 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $33.97 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,182 | 28 | Theratechnologies Inc. ($750.00) |
| 2020 | $180.16 | 9 | ViiV Healthcare Company ($103.64) |
| 2019 | $1,003 | 29 | Gilead Sciences, Inc. ($237.90) |
| 2018 | $824.02 | 28 | Gilead Sciences, Inc. ($198.01) |
| 2017 | $1,278 | 30 | Gilead Sciences Inc ($427.69) |
All Payment Transactions
124 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/25/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: HIV | ||||||
| 08/24/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: HIV | ||||||
| 08/12/2021 | Theratechnologies Inc. | TROGARZO (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: HIV | ||||||
| 08/05/2021 | Janssen Products, LP | SYMTUZA (Drug) | Education | In-kind items and services | $29.99 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/29/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: HIV | ||||||
| 07/29/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.67 | General |
| 07/22/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: HIV | ||||||
| 07/01/2021 | Merck Sharp & Dohme Corporation | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/23/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: HIV | ||||||
| 06/23/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 06/23/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $4.05 | General |
| Category: HIV | ||||||
| 06/17/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: HIV | ||||||
| 06/11/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.23 | General |
| 06/10/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: HIV | ||||||
| 06/03/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $8.81 | General |
| Category: HIV | ||||||
| 06/02/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.98 | General |
| 05/26/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: HIV | ||||||
| 05/06/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: HIV | ||||||
| 05/06/2021 | ViiV Healthcare Company | DOVATO (Drug), RUKOBIA | Food and Beverage | In-kind items and services | $8.76 | General |
| Category: HIV | ||||||
| 04/29/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 04/22/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $4.68 | General |
| Category: HIV | ||||||
| 04/08/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: HIV | ||||||
| 04/08/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $2.99 | General |
| Category: HIV | ||||||
| 04/01/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 03/30/2021 | Janssen Products, LP | SYMTUZA (Drug) | Education | In-kind items and services | $29.99 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 235 | 348 | $105,775 | $36,793 |
| 2022 | 6 | 216 | 323 | $80,217 | $33,731 |
| 2021 | 5 | 122 | 187 | $44,320 | $18,564 |
| 2020 | 4 | 141 | 223 | $52,009 | $20,237 |
Total Patients
714
Total Services
1,081
Medicare Billing
$109,324
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 60 | 143 | $39,941 | $14,304 | 35.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 74 | 78 | $35,944 | $11,428 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 61 | 80 | $12,471 | $5,164 | 41.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 19 | $8,962 | $2,964 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 17 | $5,498 | $1,722 | 31.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $2,959 | $1,211 | 40.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 61 | 151 | $30,955 | $13,199 | 42.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 66 | 68 | $27,064 | $11,382 | 42.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 54 | $7,668 | $3,261 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 22 | $5,580 | $2,420 | 43.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 17 | $5,991 | $2,258 | 37.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $2,959 | $1,211 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 39 | 88 | $18,490 | $7,788 | 42.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 35 | $14,476 | $5,878 | 40.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 33 | $4,833 | $2,001 | 41.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $4,105 | $1,735 | 42.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 16 | $2,416 | $1,163 | 48.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 50 | 51 | $21,369 | $8,326 | 39.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 75 | $16,125 | $6,599 | 40.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 40 | 66 | $9,834 | $3,770 | 38.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 31 | $4,681 | $1,542 | 32.9% |
About Dr. Richa Tandon, M.D
Dr. Richa Tandon, M.D is a Infectious Disease healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285755348.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richa Tandon, M.D has received a total of $4,467 in payments from pharmaceutical and medical device companies, with $1,182 received in 2021. These payments were reported across 124 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($3,350).
As a Medicare-enrolled provider, Tandon has provided services to 714 Medicare beneficiaries, totaling 1,081 services with total Medicare billing of $109,324. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine, Infectious Disease
- Location Providence, RI
- Active Since 04/03/2007
- Last Updated 11/07/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1285755348
Products in Payments
- TROGARZO (Drug) $837.31
- DOVATO (Drug) $371.44
- Symtuza (Drug) $293.37
- PREZCOBIX (Drug) $272.72
- Cresemba (Drug) $249.74
- ISENTRESS (Drug) $199.44
- AVYCAZ (Drug) $147.59
- SYMTUZA (Drug) $127.87
- Truvada (Drug) $112.06
- EGRIFTA (Drug) $100.33
- TRIUMEQ (Drug) $83.43
- CRESEMBA (Drug) $64.05
- JULUCA (Drug) $40.35
- RAPIVAB (Biological) $35.45
- CABENUVA (Biological) $34.97
- SUSTIVA (Drug) $33.97
- Baxdela (Drug) $30.24
- TIVICAY (Drug) $23.12
- MENACTRA (Drug) $19.29
- Trich (Device) $19.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Providence
Kenneth Mayer, M.d, M.D
Infectious Disease — Payments: $215,232
Infectious Disease $215,232
Angela Caliendo, M.d., Ph.d, M.D., PH.D
Infectious Disease — Payments: $74,183
Infectious Disease $74,183
Timothy Flanigan, Md, MD
Infectious Disease — Payments: $57,834
Infectious Disease $57,834
Maria Mileno, Md, MD
Infectious Disease — Payments: $9,583
Infectious Disease $9,583
Rami Kantor, M.d, M.D
Infectious Disease — Payments: $8,643
Infectious Disease $8,643
Susan Cu Uvin, Md, MD
Infectious Disease — Payments: $7,364
Infectious Disease $7,364